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Ebola virus VP30 and nucleoprotein interactions
modulate viral RNA synthesis
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Ebola virus (EBOV) is an enveloped negative-sense RNA virus that causes sporadic outbreaks
with high case fatality rates. Ebola viral protein 30 (eVP30) plays a critical role in EBOV
transcription initiation at the nucleoprotein (eNP) gene, with additional roles in the replication
cycle such as viral assembly. However, the mechanistic basis for how eVP30 functions during
the virus replication cycle is currently unclear. Here we deﬁne a key interaction between
eVP30 and a peptide derived from eNP that is important to facilitate interactions leading to
the recognition of the RNA template. We present crystal structures of the eVP30 C-terminus
in complex with this eNP peptide. Functional analyses of the eVP30–eNP interface identify
residues that are critical for viral RNA synthesis. Altogether, these results support a model
where the eVP30–eNP interaction plays a critical role in transcription initiation and provides a
novel target for the development of antiviral therapy.
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E
bolavirus, Marburgvirus, and Cuevavirus are members of
the Filoviridae family. Members of the Ebolavirus genus and
the Marburgvirus genus cause rare outbreaks with high case
fatality rates1,2. Ebola virus (EBOV), Sudan virus, Taı¨ Forest
virus, Bundibugyo virus, and Reston virus are species within the
genus Ebolavirus3. The recent outbreak in West Africa, which
also imported cases to non-West African countries, serves as a
reminder of the potential impact of ﬁlovirus infections on global
health (http://www.who.int/csr/disease/ebola/en). While recent
efforts to develop countermeasures that target ﬁloviruses are
starting to yield candidate therapeutics, our knowledge of the
basic biology of the virus, including key virus–virus and host–
virus interactions remain incompletely deﬁned4,5. Moreover, it is
currently unclear if the current candidate therapeutics will prove
safe and efﬁcacious in humans, and therefore the need for
antiﬁlovirals and novel targets remain.
Viral protein 30 (VP30) proteins are present in all ﬁloviruses
and perform several important functions, but homologues are
lacking in other negative-sense RNA viruses6–11. VP30 proteins
are approximately 30 kDa in size and are phosphoproteins, where
the phosphorylation state is thought to impact some but not all
VP30-mediated functions10,12. Additionally, VP30 binds RNA in
the presence of zinc7 and associates with the viral RNA synthesis
machinery, which includes nucleoprotein (NP), VP35, and large
(L) protein that contains the enzymatic activities9,12–15. EBOV
VP30 (eVP30) is critical for viral transcription (mRNA synthesis),
because it is required for initiation at EBOV NP (eNP), the ﬁrst
gene of the seven gene genome16. eVP30 has also been implicated
in regulation of co-transcriptional editing of viral glycoprotein
mRNAs and in modulation of viral transcription reinitiation11,17.
In contrast to the studies on eVP30, there does not appear to be a
requirement for VP30 in Marburg virus (MARV) transcription
initiation, at least when measured using model viral RNA
templates. Nonetheless, attempts to generate replication-
competent VP30 deletion MARVs were unsuccessful, suggesting
an essential role in virus growth18 and potentially additional roles
for VP30 in MARV and in EBOV. eVP30 has been shown to
interact with eVP35 and with eNP, and these interactions may
modulate viral transcription and incorporation of viral genomic
RNAs into new viral particles12,15. An additional report suggested
that VP30 interacts with the viral polymerase L13.
The studies described above collectively point to signiﬁcant
roles played by eVP30 through various intermolecular interac-
tions, which likely occur at different stages of the virus replication
and infection cycles. While these interactions have been
previously identiﬁed, we currently lack a molecular description
of them. Importantly, we do not know how these interactions
regulate function. Deﬁning mechanisms by which eVP30
modulates viral RNA synthesis and other aspects of viral
replication also has the potential to identify novel therapeutic
targets. Because the interaction of eVP30 with eNP may play roles
in viral transcription and assembly, we investigated here how
eVP30 and eNP interact with each other, leading to a biochemical
and structural deﬁnition of the binding interface. We demon-
strate that eVP30 binds directly to eNP. We show that mutation
of a subset of VP30 residues important for NP binding results in
loss of RNA synthesis, while mutation at other sites do not.
Moreover, mutation of multiple residues on NP involved in VP30
binding also results in loss of function. We also note that the
signiﬁcance of this interaction depends on a speciﬁc secondary
structure of the RNA template16. This stem loop, which was
previously identiﬁed as an eVP30 interactor, dictates whether
eVP30/eNP interaction is required or dispensable for
minigenome (MG) activity. Consistent with this observation,
in our modiﬁed MG assay (MGA), we show that this speciﬁc
stem loop that interacts with eVP30 may control virus replication
and transcription in infected cells. Collectively, our data reveal
new insights that address the enigmatic nature of VP30 function
and, importantly, deﬁne novel targets for therapeutic
development, including eVP30–eVP30 and eVP30–eNP
interaction sites.
Results
A peptide derived from eNP binds VP30. In order to gain
molecular mechanistic insight into how eVP30/eNP interaction
promotes viral RNA synthesis, we generated a series of recom-
binant eVP30/eNP truncation constructs (Fig. 1a; Supplementary
Fig. 1). Initially, we tested eVP30/eNP protein–protein interac-
tions by in vitro pull-down assays, which revealed that a region
encompassing residues 600–610 in eNP is critical for eVP30
interactions (Fig. 1b; Supplementary Fig. 2a–e). This region of
eNP was absent in the solved crystal structures of the eNP
C-terminus (residues 642–739; PDB 4QB0, 4QAZ (ref. 19), Tai
Forest NP (tNP; PDB: 5E2X) and Bundibugyo virus NP
C-terminus (residues 642–739; PDB 5DSD)20 and therefore
represents a new ﬁnding. Next, we optimized the crystallization
by varying constructs (eNP600–739 and eVP30110–272) and
characterized this interaction by size-exclusion chromatography
coupled to multi-angle light scattering. These results indicate that
eVP30110–272 behaves as a dimer while eNP600–739 is a monomer
in solution (Fig. 1c). Upon mixing, eNP600–739 and eVP30110–272
form a 1:1 heterodimer complex (Fig. 1c; Supplementary Fig. 2f–
h). Consistent with this, isothermal titration calorimetry (ITC)
experiments revealed that eNP and eVP30 bind
with 3.75±1.7 mM afﬁnity and 0.8±0.2 stoichiometry, with
± denoting s.d. of triplicate replicates (Fig. 1d). Together, the
size-exclusion chromatography coupled to multi-angle light
scattering and ITC data suggest that complex formation leads
to loss of VP30 dimerization. Of note, the eVP30110–272 construct
lacks the major dimerization site deﬁned previously21, suggesting
that additional regions within VP30 are involved in
oligomerization and regulation of VP30 function12.
We generated protein crystals for structure determination
using the puriﬁed eVP30110–272/eNP600–739 complex. Initial low-
resolution diffracting crystals were optimized by in situ proteo-
lysis and resulted in several well-diffracting crystals. The two
highest-resolution data crystal forms were solved by molecular
replacement using the Reston virus VP30 structure (PDB 3V7O)
as the search model and were reﬁned iteratively are described
here (Fig. 2 and Table 1). In the structures, we observe eNP
residues 602–612 with residues 140–252 (5VAP) and residues
140–266 of eVP30 (5VAO). Comparisons between molecules
within each asymmetric unit (two complexes in 5VAP and four
complexes in 5VAO) as well as comparisons of structures across
different space groups revealed minimal conformational pertur-
bations. For example, heavy atom pairwise root-mean-square
deviation for eVP30 (residues 140–266) ranges from 0.4 to 1.1 Å,
while similar comparisons for eNP result in a pairwise root-
mean-square deviation of 0.3–1.3 Å. In contrast to eVP30/eNP
contacts, which are largely similar even though the structures
belong to different asymmetric units, the ternary conﬁgurations
of eVP30 suggest that the eVP30/eNP interaction may not impact
eVP30–eVP30 interactions (Fig. 2). However, it is important
to note that our in vitro data suggest that the interaction
between eNP and eVP30 can impact the oligomerization state of
eVP30 in solution. These differences may play a critical role
in a context-dependent manner during virus replication and
assembly. Comparison of the eVP30 structure for residues
142–266 between VP30-bound and -free show limited structural
changes (Supplementary Fig. 3). Given the overall agreement
among the eVP30/eNP 1:1 complexes, we used complex A
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from 5VAP as representative structures for analyses and
discussions below.
Interface between eVP30 and eNP is highly conserved. Residues
from eNP that span 600–612 are highly conserved not only across
all ebolavirus genus members but also marburgvirus as well
(Supplementary Fig. 1a). Sequence analysis of human proteins
suggests that this 13 residue sequence observed in our structure is
not a common eukaryotic sequence. Moreover, given the struc-
tural requirements that are critical for binding, the likelihood of a
host factor mimicking the eNP peptide sequence is low. Although
PPXP motifs typically form a left-handed turn, in the eNP/eVP30
complex structures, the conformation of this motif does not form
the expected polyproline type II helix. Instead, these highly
conserved eNP residues make extensive contacts with eVP30
residues in an extended conformation (Fig. 3a). Although the
binding pocket is somewhat shallow, the interaction site displays
a shape complementarity (Sc) score of 0.6, which is considered
signiﬁcant. For comparison, antibody–antigen complexes have Sc
scores of around 0.72. Moreover, examination of the electron
density of the unbiased map (Supplementary Fig. 4a) or the ﬁnal
reﬁned map (Fig. 3b) shows clear density for the secondary
structure with B-factors comparable to nearby residues of eVP30,
further supporting the relevance of the crystallographically
identiﬁed interface. Analysis of the interface reveals that there are
seven hydrogen bonds between eVP30 and eNP (Fig. 3c) and a
number of hydrophobic contacts, which make up much of the
observed total of 1,923Å2 buried surface area.
Select interface residues are important for RNA synthesis. In
order to experimentally validate the interface between eVP30 and
eNP, we developed a ﬂuorescence polarization assay (FPA) to
evaluate effects of mutating interface residues on eVP30 and eNP
binding. Peptides corresponding to eNP residues 600–615, which
we termed EBOV VP30-binding peptide (eVP30BP), were con-
jugated to ﬂuorescein isothiocyanate (FITC-eVP30BP). FPA was
performed by increasing eVP30 concentration (Supplementary
Fig. 4b) in the presence of FITC-eVP30BP to monitor the
ﬂuorescence decrease as a result of the slower tumbling of FITC-
eVP30BP after binding to eVP30. In competition FPA, constant
concentrations of FITC-eVP30BP and eVP30110–272 were incu-
bated with increasing concentrations of unlabelled eVP30BP
competitor (Supplementary Fig. 4c). Both types of experiments
display a high dynamic range of 4100 and 450 arbitrary units,
respectively. Using these FPAs, we tested mutants of eNP and
eVP30 and identiﬁed a number of amino acid residues that
showed in a minor decrease in binding when individually
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Figure 1 | eVP30 binds eNP with high speciﬁcity. (a) Constructs of eNP (top) and eVP30 (bottom) used in this study. (b) Summary of in vitro pull-down-
based binding results for a series of truncation constructs for eNP. þ , binding;  , no binding. (c) Size exclusion chromatography coupled to multi-angle
light scattering results for eVP30110–272 (black; molecular weight (MW) 38.7±0.030 kDa), eNP600–739 (red; MW 16.8±0.030 kDa) and eVP30110–272-
eNP600–739 complex (green; MW 39.6±0.030 kDa). The calculated MW for monomeric eVP30110–272, dimeric eVP30110–272 and eNP600–739 are 18.7, 37.3
and 17.03 kDa, respectively. The calculated MW for a 1:1 complex of eVP30110–272–eNP600–739 is 35.7 kDa. (d) Representative ITC binding isotherm for the
1:1 complex between eVP30110–272 and eNP600–739. KD¼ 3.75±1.7mM. (Also see Supplementary Fig. 1). Error represents s.d.
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little or no impact on eVP30 binding while multi-residue mutants
(603-606AAGG and 610-612AAA) resulted in a near complete
loss of binding to eVP30 wild type (WT), suggesting that NP
contributes a large number of redundant contacts to eVP30
binding. Consistent with this ﬁnding, co-immunoprecipitation of




























































Figure 2 | A peptide derived from eNP binds eVP30 using the same interface despite different VP30 complexes in the asymmetric unit. Cartoon (top)
and surface (bottom) representations of the following complexes are shown: (a) 2:2 ratio of eVP30 (green) and eNP (magenta). (b) 4:4 ratio of eVP30
(green) and eNP (magenta). (Also see Supplementary Fig. 1).
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correspond to our in vitro FPA results (Fig. 4b). When we tested
eVP30 mutants, we found that some single eVP30 mutations, but
not others, resulted in loss of binding to eNP WT. For example,
eVP30 Q203A or R213A or Q229A did not result in loss of
binding to eNP WT in the FPA, whereas eVP30 E197A and
W230A resulted in a near complete loss of binding (Fig. 4c–e).
We next assessed the eVP30/eNP interface using an Ebola
minigenome assay (MGA), which reports on viral RNA
synthesis22. We observed that mutations in eVP30, such as
Q203A and Q229A (which slightly affect binding) or E197A
(which largely abrogates binding between eVP30/eNP), have
limited impact in the MG activity (Fig. 5a). Furthermore, this was
also true for eNP mutants when tested in the MGA. The multiple
eNP residue mutants that completely abrogated binding to eVP30
such as 603–606 AAGG and 610–612 AAA (Fig. 4b) also showed
less MG activity upon titration of eNP residue mutants (Fig. 5b).
Interestingly, the individual residue mutants of eNP, which only
minimally affected binding, had little effect on MG activity as
well. These results suggest that a high-afﬁnity interaction at the
site we observe in our crystal structure between eVP30 and eNP
via the eVP30BP is not strictly required for viral RNA synthesis.
Moreover, our data suggest that even minimal binding between
eVP30-eNP is sufﬁcient for this interaction to function in viral
RNA synthesis. However, our data show that the binding site
identiﬁed in our structure, which includes residues such as W230,
results in complete loss of binding and corresponding loss of
activity in viral RNA synthesis. Although the direct impact of
W230 in viral RNA synthesis is unclear, given the importance of
eNP/eVP30 interaction deﬁned in the crystal structure, it is likely
that sustained interaction is required for viral replication.
However, an alternative possibility is that the molecule may
lose structure due to the loss of hydrophobic contact and stability.
eVP30 and eNP interaction recognizes RNA stem loop. To
further determine the relevance of the eNP binding to eVP30 in
viral RNA synthesis, we performed experiments to compare
results from WT and mutant MG templates. The mutant MG has
a mutation in a stem-loop RNA structure that corresponds to one
in the 50UTR (untranslated region) region of eNP, which renders
EBOV transcription VP30 dependent16. The resulting data,
consistent with previously published studies16, revealed that the
mutant MG can function in a VP30-independent manner
(Supplementary Fig. 4d). Viral RNA synthesis was assessed with
either eVP30 or eVP30 mutants using either WT or mutant MG
assays. From this data, we ﬁnd that mutant MG activity was
comparable to the WT MG activity for all eVP30 mutants
(Fig. 6a). In addition, we observe that eVP30 mutants that were
signiﬁcantly inhibited in the WT MG assay, including the W230A
mutant (and Q229A/W230A), were functional in the mutant MG
assay (Figs 5a and 6a). These results suggest that these mutants
that lack activity with the WT MG are defective in viral
transcription initiation. Given that some mutations within the
interface do lose activity, this suggests that the residues involved
in the interaction play an additional role in viral transcription.
We further evaluated whether this highly conserved eNP
region (600–615 residues) that makes contacts with eVP30
(eVP30-binding peptide) has the ability to affect viral RNA
synthesis. We generated a green ﬂuorescent protein (GFP) fusion
with the eNP 600–615 region (GFP-eVP30BP) and tested its role
in the MG assay. These results, shown in Fig. 6b, revealed that
GFP-eVP30BP but not GFP alone resulted in dose-dependent
inhibition of MG activity. This result suggests that the eVP30BP
from eNP makes contact with eVP30 in the context of the viral
RNA polymerase complex and has the potential to inhibit viral
RNA synthesis. We also tested the effect of GFP-eVP30BP in the
presence of eVP30 mutants that are unable to bind to NP
(Fig. 7a). The effect of this peptide on MG activity correlated to
the binding afﬁnities of each eVP30 residues to eNP. For example,
the MG activity with WT eVP30 was inhibited in the presence of
peptide. MG activity with single eVP30 mutants that largely bind
to eNP (D202A, Q203A or Q229A) were also inhibited by
peptide. However, the peptide failed to inhibit MG activity with
eVP30 E197A, which does not bind to eNP. We also evaluated the
effect of peptide using the 50UTR mutant MG construct (Fig. 7b).
The presence of peptide had no effect on activity with this mutant
MG template, suggesting that this peptide inhibits VP30-
dependent viral RNA synthesis. Cumulatively, these results
indicate that there are eVP30/eNP-dependent and -independent
components of Ebola viral RNA synthesis. The eVP30–eNP
component can be targeted by the eNP peptide in the context of
the viral polymerase complex and inhibit viral synthesis.
Discussion
Our results described above deﬁne how eVP30 interactions with
eNP impact EBOV RNA synthesis and identify novel targets for
virus-directed therapeutic development. Speciﬁcally, we use an
eNP-derived peptide and show that the VP30-binding site can be
Table 1 | Data collection and reﬁnement statistics.
PDB ID 5VAP 5VAO
Data collection
Space group P212121 I4122
Unit cell parameters
a, b, c (Å) 48.5, 55.1, 114.6 139.8, 139.8, 161.7
a, b, g () 90, 90, 90 90, 90, 90
Resolution range (Å) 50–1.85 (1.88–1.85)* 50–2.55 (2.59–2.55)
Rmerge (%) 0.058 (0.636) 0.109 (0.982)
I/s(I) 33.9 (2.1) 19.6 (1.0)
Completeness (%) 99.6 (100.0) 99.7 (94.9)
Redundancy 4.8 (4.8) 7.6 (4.3)
CC1/2 0.804 0.578
Reﬁnement
Resolution (Å) 57.31–1.85 105.55–2.56
No. of reﬂections 24,591 21,271
Rwork/Rfree (%) 20.6/24.4 19.4/23.3

















Bond lengths (Å) 0.023 0.015




MolProbity score 0.91 1.21
MolProbity clashscore 1.64 4.34
*Highest resolution shell is shown in parenthesis.
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a target for peptide or peptide-mimic therapeutics as well as its
utility for high-throughput assay. Our structural and cell
biological studies, which are highlighted in Supplementary
Table 1, provide a molecular mechanism by which the interaction
between eVP30 and eNP promotes RNA synthesis of EBOV MG
activity. While we identify speciﬁc molecular interfaces, which
were validated using a novel competition assay in order to
demonstrate the relevance of our studies and to deﬁne a key
conserved interface, we also show that the regulatory interactions
between eVP30 and eNP are more complex than originally
appreciated. Our studies also show that eVP30/eNP interaction
can impact the oligomeric state of eVP30, which may be
functionally relevant. Importantly, we show that a subset of the
eVP30/eNP interaction deﬁned by our study is critical for viral
RNA synthesis in a RNA secondary structure-dependent manner,
while others may be dispensable. It is important to note that our
results presented here point to the signiﬁcance of eVP30/eNP in
RNA synthesis initiation, but previous studies indicate that
eVP30 may also play a role as a transcriptional activator. Both of
these activities likely depend on eVP30/eNP interactions, which
further enhance the signiﬁcance to viral RNA synthesis. A recent
study of the Ebola viral VP30/NP concluded that this interaction
is as a regulator of viral RNA synthesis23. This observation is
consistent with the results reported here. Together, these studies
highlight the signiﬁcance of this VP30/NP interaction, and in
particular, we show that this interaction, at least in part, is
signiﬁcant for recognition of a critical stem loop in the viral UTR.
Further efforts to examine this interaction for therapeutic
development are likely to result in new insights into the
complex molecular mechanism of ﬁloviral RNA synthesis.
Methods
Constructs. Full-length Ebola Zaire VP30 (eVP30) gene (GenBank ID
KY425656.1) was used as a template to generate PCR products for eVP3069–288,
eVP3089–288 and eVP30110–272 constructs that were ligated into a modiﬁed pET
vector (Novagen). Resulting vectors were veriﬁed by sequencing before use. EBOV
eNP437–739, eNP564–739, eNP590–739, eNP600–739, eNP610–739 and eNP641–739 were
cloned similarly.
Protein expression and puriﬁcation. All eVP30 and eNP proteins were expressed
as maltose-binding protein (MBP) fusion proteins in BL21(DE3) E. coli cells
(Novagen) in Lysogeny broth media. Protein expression was induced at an optical
density of 0.6 with 0.5mM isopropylthiogalactoside and grown for 12–15 h at
18 C. Cells were harvested and resuspended in lysis buffer containing 25mM
sodium phosphate pH 7.5, 250mM NaCl, 20mM imidazole and 5mM 2-mecap-
toethanol. Then cells were lysed using an EmulsiFlex-C5 homogenizer (Avestin)
and clariﬁed by centrifugation at 30,000g at 4 C for 30min. eVP30 and eNP
constructs were puriﬁed using a series of afﬁnity and ion exchange chromato-
graphic columns. The MBP tag was cleaved using TEV protease prior to a ﬁnal
application on a size-exclusion column. The purity of the samples was determined
by SDS–PAGE. For eVP30/eNP complexes, puriﬁed eVP30 and eNP proteins were
mixed in a 1:1.1 ratio, puriﬁed on a Superdex 75 column (GE Healthcare) and
concentrated to 20mgml 1.
In vitro pull-down assays. Amylose resin was pre-equilibrated with buffer
(20mM Tris, pH 7.5, 150mM NaCl, 5mM 2-mecaptoethanol) prior to the addition
of lysate containing recombinantly expressed MBP-tagged proteins at 4 C. Resin
was incubated for 10min, followed by washes and subsequent resuspension in
buffer. Cell lysate of cells expressing either WT or mutant versions of eNP and
eVP30 were applied to the resin and allowed to incubate for 20min, prior to
washes and ﬁnal resuspension in buffer. Samples were taken at each step and
visualized by Coomassie blue staining of SDS–PAGE.
Isothermal titration calorimetry. Quantitative analysis of eVP30/eNP complex
binding was performed on a VP-isothermal titration calorimeter (VP-ITC)
(Microcal). Protein samples were dialysed against 500ml of buffer containing
10mM HEPES (pH 7.0), 150mM NaCl and 2mM tris(2-carboxyethyl)phosphine
for 12 h at 25 C. Titrations were set up with 50–100 mM protein in the syringe and
4–10 mM protein in the cell. ITC titrations were carried out using a reference power
of 4 mcal s 1. The resulting ITC data were processed and ﬁt to a one-site-binding
model to determine n (number of binding sites) and KD (dissociation constant)
using the ORIGIN 7.0 software. All experiments were performed at least in
duplicate.
Protein crystallization. The initial crystallization condition was obtained by
screening Hampton Research kits using the vapour diffusion sitting drop method.























































Figure 3 | eNP binds within a highly conserved narrow groove within eVP30 via a combination of hydrophobic and electrostatic interactions.
(a) eVP30 residues (green) involved in interactions with eNP are shown in stick representation (blue) and labelled. The eNP peptide is shown in stick
representation (purple). (b) Stick representation of the eNP peptide residues 602–612 (purple) with a 2s electron density map (sigma-weighted 2Fo-Fc;
blue mesh). Orientation is 45 rotated from the orientation in a. (c) LigPlotþ representation of the protein–protein interactions between eVP30 (green)
and eNP (purple). Protein side chains are shown as ball and sticks. Hydrogen bonds are shown as green dotted lines. Spoked arcs represent non-bonded
contacts and the length of the arc represents the extent of the interaction. (Also see Supplementary Fig. 3).
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Figure 4 | Effects of eNP interface residue mutations on eVP30 binding. (a) FP competition assay measuring binding between eNP590–739 WT and
mutants and FITC-labelled eVP30BP. Error bars represent s.d. of at least three experiments. (b) Immunoprecipitation (top) and corresponding western
blots (bottom) of mutant HA-eNP with WT Flag-eVP30. (c) FITC–eVP30BP binding with WTor mutant eVP30110–272 measured by FP. Error bars represent
s.d. of at least three experiments. (d,e) Co-immunoprecipitation of WT HA-eNP full length with WT or mutant FLAG-eVP30 full length. IP,
immunoprecipitation; IB, immunoblot; WCE, whole-cell extract; E, empty vector.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms15576 ARTICLE
NATURE COMMUNICATIONS | 8:15576 | DOI: 10.1038/ncomms15576 | www.nature.com/naturecommunications 7
a 1:2,000 ratio (trypsin: eVP30110–272/eNP600–739 complex). From the initial pri-
mary screens, we observed about 10 conditions in which protein crystals appeared
after 1 month and these crystals diffracted to 5–6Å. Next, we used initial hits as
seeds using homemade optimization grids in order to obtain crystals that diffracted
to 1.85–3.8 Å. The ﬁnal data sets came from the following growth conditions: 0.2M
potassium phosphate monobasic and 20% PEG3350 for data 5VAP, and 0.2M
calcium chloride dehydrate and 20% w/v PEG3350 for data 5VAO. Crystals
appeared between 1 and 3 months at 20 C and growth continued for another 2–6
months upon initial appearance. Crystals were vitriﬁed in a solution containing the
mother liquor plus 25% glycerol by plunge freezing in liquid nitrogen. Protease
concentrations ranged from 1:10 to 1:500 protease to viral protein complex con-
centration (w/w).
Data collection and structure determination. Crystallographic data were col-
lected at Advanced Photon Source beamline 19ID (Argonne National Laboratory).
Over 200 images of 0.5 degree oscillation were collected at a crystal-to-detector
distance of 300mm with an attenuation of 3. Resulting images were processed by
HKL3000 (refs 24,25). Molecular replacement was carried out with Reston virus
VP30 structure (PDB ID: 3V7O) as a search model with Phaser26. The eNP
residues were built by three cycles of Bucanneer27 as implemented within CCP4
(ref. 28), followed by subsequent manual model building in COOT29. Reﬁnement
was carried out with REFMAC5 (ref. 30). Structure quality was assessed with
MolProbity31.
Fluorescence polarization assays. FPA was performed on a Cytation5 plate
reader (BioTek) operating on the Gen5 software. Excitation and emission wave-
lengths were set to 485 and 528 nm, respectively, with a band pass of 20 nm. Read
height and G factor were set to 8.5mm and 1.26 using the autogain function. FITC-
labelled eVP30BP peptide at a ﬁnal concentration of 0.5 mM was loaded onto
eVP30110–272 samples (10mM HEPES (pH 7.0), 150mM NaCl and 2mM tris(2-
carboxyethyl)phosphine) at concentrations ranging from 120 to 0.031 mM with 2.5-
fold dilution in a 96-well plate. After 10min of incubation, FP signals were read. FP
values were then plotted against eVP30110–272 concentrations, and the dissociation
constant, KD, was ﬁtted using the following equation for each mutant:
F ¼ Fbound  Ffreeð Þ KD þ LtotþRtotð Þ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ




where Fbound is the FP when FITC-eVP30BP is saturated with eVP30 WT or
mutants, Ffree the FP of free FITC-eVP30BP, KD dissociation constant, Ltot the total
ligand concentration and Rtot the total receptor concentration.
For competition experiments, FITC-labelled eVP30BP peptide at a ﬁnal
concentration of 0.125mM was mixed with 1 mM of VP30110–272 and eNP590–739
WT or mutants were added at concentrations ranging from 500 to 0.05 mM with
two-fold dilution in a 96-well plate. After 20min of incubation, FP signals were
read. FP values were then plotted against eNP WT or mutant concentrations, and
the dissociation constant, KD, was ﬁtted using the following equation for each
mutant:
F ¼ Ffree þ Fbound  Ffree
KD Ctot þ k2k2L þ 1
where Ffree is FP of free FITC-eVP30BP, Fbound is FP of FITC-eVP30BP saturated
with eVP30110–272, KD is the dissociation constant of eVP30110–272 with FITC-
eVP30BP, Ctot is the concentration of added competitor protein, k2 is the
dissociation constant of eNP590–719 with eVP30110–272 and L is concentration of
eNP590–739 WT or mutants.
Co-immunoprecipitation assays. Twenty-four hours post-transfection with the
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Figure 5 | Interaction between eVP30 and eNP observed in the crystal structure is not strictly required for viral RNA synthesis. MGA was performed
using (a) WTand select interface mutants of eVP30 (50, 100, 200ng) and (b) WTand select interface mutants of eNP (125, 250, 500ng) (western blots
represent the expression of eNP at 500ng). Representative western blots are shown. Errors represent s.d. of at least three experiments.
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buffer (50mM Tris [pH 7.5], 280mM NaCl, 0.5% Nonidet P-40, 0.2mM EDTA,
2mM EGTA, 10% glycerol, protease inhibitor (cOmplete; Roche)) and phosphatase
inhibitor (PhosSTOP; Roche). Anti-HA magnetic beads (Sigma-Aldrich) were
incubated with lysates for 1 h at 4 C, washed ﬁve times in NP-40 lysis buffer and
eluted using either HA peptide (Sigma-Aldrich). Precipitates and whole-cell lysates
were analysed by western blot.
MG assay and mutant-MG assay. HEK293T cells were transfected using Lipo-
fectamine 2000 (Invitrogen) with plasmids encoding viral proteins: pCAGGS-L, -
VP35, -NP or NP mutant constructs, -VP30, or VP30 mutant constructs along with
pCAGGS-T7 polymerase32,33 and pTM1 MG reporter plasmid34 that encodes
Renilla reporter gene ﬂanked by cis-acting regulatory sequences from virus.
pCAGGS plasmid is available through Addgene (https://www.addgene.org/) and
the modiﬁed plasmids containing Ebola proteins are available through the authors.
Some MG assays was also performed using a mutant MG reporter construct
(mut MG) in which the stem-loop structure in the highly conserved transcription
start signal of the NP gene (50UTR) was disrupted where VP30 binds16,22. A
constitutively active ﬁreﬂy plasmid (Promega) was also transfected to assess the
transfection efﬁciency. Forty-eight hours post-transfection, the cells were lysed
using Passive Lysis buffer (Promega) and luciferase activities were assessed using a
dual luciferase reporter assay (Promega). The Renilla luciferase values were
normalized to ﬁreﬂy luciferase values.
Antibodies. Monoclonal mouse anti-FLAG M2 antibody (Sigma Aldrich, F1804,
1mgml 1), polyclonal rabbit anti-Flag antibody (Sigma Aldrich, F7425,
0.8mgml 1), monoclonal mouse anti-HA antibody (Sigma Aldrich, H3663,
1mgml 1) and polyclonal rabbit anti-HA antibody (Sigma Aldrich, H6908,
1mgml 1) were purchased from Sigma-Aldrich. All antibodies were used between
0.8 and 1mgml 1 for western blots.
Structural ﬁgure generation and analysis. All structure analyses were carried out

































































































































Figure 6 | Additional residues at the eVP30 and eNP interface may be important for viral RNA synthesis and transcription. (a) VP30 interface mutants
with WT (dark grey bar) or stem-loop 50UTR mutant MG template (light grey bar). (b) The MG assay was performed in the presence of either GFP control
plasmid or plasmid consisting of GFP-eVP30BP (used at 50, 500ng). The effect of GFP-eVP30BP (500ng) was examined on the WT-MG. Representative
western blots are shown. Errors represent s.d. of at least three experiments.
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and Sc, respectively, were used for interaction surface analysis. Final structure
ﬁgures were prepared using PyMOL35 and the protein–protein interactions were
analysed using DIMPLOT as implemented in LigPlotþ (ref. 36).
Data availability. Structures for eVP30/eNP complex have been deposited in the
Protein Data Bank (http://www.rcsb.org) under accession codes 5VAP and 5VAO.































































































































































































































































































































































































































































































































Figure 7 | eVP30BP inhibits VP30-dependent viral RNA synthesis. (a) WT MG or 50UTR mutant MG template (b) in the presence of VP30 interface
mutants. The corresponding western blots for each MG assay is shown below each chart. (Also see Supplementary Fig. 4). The MG data and representative
western blots are shown. Errors represent s.d. of at least three experiments.
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